Recent Progress in Multiple Sclerosis Treatment Using Immune Cells As Targets

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Mar 29

PMID 36986586

Authors

Xiaohong Ma

Rong Ma

Mengzhe Zhang

Baicheng Qian

Baoliang Wang

Weijing Yang

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) is an autoimmune-mediated demyelinating disease of the central nervous system. The main pathological features are inflammatory reaction, demyelination, axonal disintegration, reactive gliosis, etc. The etiology and pathogenesis of the disease have not been clarified. The initial studies believed that T cell-mediated cellular immunity is the key to the pathogenesis of MS. In recent years, more and more evidence has shown that B cells and their mediated humoral immune and innate immune cells (such as microglia, dendritic cells, macrophages, etc.) also play an important role in the pathogenesis of MS. This article mainly reviews the research progress of MS by targeting different immune cells and analyzes the action pathways of drugs. The types and mechanisms of immune cells related to the pathogenesis are introduced in detail, and the mechanisms of drugs targeting different immune cells are discussed in depth. This article aims to clarify the pathogenesis and immunotherapy pathway of MS, hoping to find new targets and strategies for the development of therapeutic drugs for MS.

Citing Articles

Microglial Mayhem NLRP3 Inflammasome's Role in Multiple Sclerosis Pathology.

Fan H, Fu Q, Du G, Qin L, Shi X, Wang D CNS Neurosci Ther. 2024; 30(12):e70135.

PMID: 39690733 PMC: 11652677. DOI: 10.1111/cns.70135.

Regulatory T Cells in Multiple Sclerosis Diagnostics-What Do We Know So Far?.

Arneth B J Pers Med. 2024; 14(1).

PMID: 38248730 PMC: 10821144. DOI: 10.3390/jpm14010029.

Microglia subtypes in acute, subacute, and chronic multiple sclerosis.

Prineas J, Lee S J Neuropathol Exp Neurol. 2023; 82(8):674-694.

PMID: 37344153 PMC: 10357941. DOI: 10.1093/jnen/nlad046.

References

Mohammad M, Hassanpour M, Tsai V, Li H, Ruitenberg M, Booth D . Dendritic cells and multiple sclerosis: disease, tolerance and therapy. Int J Mol Sci. 2012; 14(1):547-62. PMC: 3565281. DOI: 10.3390/ijms14010547. View

Peng H, Guerau-de-Arellano M, Mehta V, Yang Y, Huss D, Papenfuss T . Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012; 287(33):28017-26. PMC: 3431702. DOI: 10.1074/jbc.M112.383380. View

Cencioni M, Mattoscio M, Magliozzi R, Bar-Or A, Muraro P . B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nat Rev Neurol. 2021; 17(7):399-414. DOI: 10.1038/s41582-021-00498-5. View

Gharibi T, Babaloo Z, Hosseini A, Marofi F, Ebrahimi-Kalan A, Jahandideh S . The role of B cells in the immunopathogenesis of multiple sclerosis. Immunology. 2020; 160(4):325-335. PMC: 7370136. DOI: 10.1111/imm.13198. View

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

Fletcher J, Lalor S, Sweeney C, Tubridy N, Mills K . T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010; 162(1):1-11. PMC: 2990924. DOI: 10.1111/j.1365-2249.2010.04143.x. View

Schreiber F, Arasteh J, Lawley T . Pathogen Resistance Mediated by IL-22 Signaling at the Epithelial-Microbiota Interface. J Mol Biol. 2015; 427(23):3676-82. DOI: 10.1016/j.jmb.2015.10.013. View

Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G . Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013; 5):CD002127. PMC: 11745300. DOI: 10.1002/14651858.CD002127.pub3. View

Cryan J, ORiordan K, Sandhu K, Peterson V, Dinan T . The gut microbiome in neurological disorders. Lancet Neurol. 2019; 19(2):179-194. DOI: 10.1016/S1474-4422(19)30356-4. View

10.

Di Somma C, Scarano E, Barrea L, Zhukouskaya V, Savastano S, Mele C . Vitamin D and Neurological Diseases: An Endocrine View. Int J Mol Sci. 2017; 18(11). PMC: 5713448. DOI: 10.3390/ijms18112482. View

11.

Oreja-Guevara C, Ramos-Cejudo J, Aroeira L, Chamorro B, Diez-Tejedor E . TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. BMC Neurol. 2012; 12:95. PMC: 3517482. DOI: 10.1186/1471-2377-12-95. View

12.

Montes Diaz G, Hupperts R, Fraussen J, Somers V . Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies. Autoimmun Rev. 2018; 17(12):1240-1250. DOI: 10.1016/j.autrev.2018.07.001. View

13.

Chen M, Chen G, Deng S, Liu X, Hutton G, Hong J . IFN-β induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol. 2011; 242(1-2):39-46. DOI: 10.1016/j.jneuroim.2011.10.014. View

14.

Rasouli J, Ciric B, Imitola J, Gonnella P, Hwang D, Mahajan K . Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy. J Immunol. 2015; 194(11):5085-93. PMC: 4433790. DOI: 10.4049/jimmunol.1403243. View

15.

Sellebjerg F, Hesse D, Limborg S, Lund H, Sondergaard H, Krakauer M . Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. Mult Scler. 2012; 19(2):179-87. DOI: 10.1177/1352458512450353. View

16.

Lehmann-Horn K, Wang S, Sagan S, Zamvil S, von Budingen H . B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue. JCI Insight. 2016; 1(20):e87234. PMC: 5135275. DOI: 10.1172/jci.insight.87234. View

17.

Severa M, Rizzo F, Giacomini E, Salvetti M, Coccia E . IFN-β and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks. Cytokine Growth Factor Rev. 2014; 26(2):229-39. DOI: 10.1016/j.cytogfr.2014.11.005. View

18.

Dhib-Jalbut S . Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 2002; 58(8 Suppl 4):S3-9. DOI: 10.1212/wnl.58.8_suppl_4.s3. View

19.

Xu W, Li R, Dai Y, Wu A, Wang H, Cheng C . IL-22 secreting CD4+ T cells in the patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol. 2013; 261(1-2):87-91. DOI: 10.1016/j.jneuroim.2013.04.021. View

20.

Namdar A, Nikbin B, Ghabaee M, Bayati A, Izad M . Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. J Neuroimmunol. 2009; 218(1-2):120-4. DOI: 10.1016/j.jneuroim.2009.10.013. View